|
KMID : 0391319930030020239
|
|
Korean Journal of Biological Response Modifiers
1993 Volume.3 No. 2 p.239 ~ p.0
|
|
|
Effects of rh-G-CSF on Lenkocyte and Differential Counts in Stomach Cancer Patients Receiving EAP Chemotherapy
|
|
홍원선
김창민/김유철/이진오/이동순/홍석일
|
|
|
Abstract
|
|
|
Background:
@EN Recent advancement of genetic techniques has made it possible to produce a large amount of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and enable its clinical application to a variety of neutropenia. We have previously
demonstrated that leukocyte and neutrophil counts were significantly elevated with two peaks by the treatment with chemotherapy followed by rhG-CSF, rhG-CSF is known to interact with target cells by binding to the high affinity receptors on cell
surfaces and the receptors are found in various types of hematopoeitic cells. This study was conducted to investigate what kinds of leukocyte and leukocyte precursor cells. This study was conducted to investigate what kinds of leukocyte and
leukocyte
precursor cells increased in the peripheral blood after the administration of rhG-CSF.
@ES Methods:
@EN Eight patients with unresectable stomach cancer were treated with two cycles of EAP chemotherapy. In the first cycle, as a control course, patients received EAP chemotherapy alone, while in the second cycle, as a treatment course, rhG-CSF was
given
subcutaneously from three days after the termination of chemotherapy for 14 days. Leukocyte and differential counts in the nadir were compared with those before the chemotherapy in the first cycle. In the second cycle, leukocyte and differential
counts
in the first peak, nadir and the second peak, nadir and the second peak were compared with those before the chemotherapy.
@ES Results:
@EN In the first cycle, leukocyte, neutrophil and monocyte counts decreased gradually and subsequently increased after the nadir to the inital levels. In the second cycle, rhG-CSF significantly elevated leukocyte and neutrophil counts in the
peripheral
blood with a biphasic shape consisting of the first peak, nadir and the second peak. Leukocyte, neutrophil and large unstained cell (LUC) counts in the first and second peak were significantly elevated compared with those before the chemotherapy.
The
nadir counts of leukocytes, neutrophils and LUCs significantly decreased compared with those before the chemotherapy in the second cycle. However, lymphocyte, monocyte, esosinophil and basophil counts in the first peak, nadir and the second peak
were
not significantly different from those before the chemotherapy. The nadir count of monocytes in the second cycle was not decreased by the treatment with rhG-CSF, although its nadir count significantly deceased in the first cycle. No significant
differences in days to reach the nadirs of leukocytes and in nadir counts of leukocytes and neutrophils were observed between the first and the second cycle. rhG-CSF significantly shortened the period of leukopenia, <4,000/㎣, and neutropenia,
<2,000/㎣. The recovery time required for leukocytes and netrophils to reach≥4,000/㎣ and ≥2,000/㎣ after the nadir, respectively, was significantly reduced in the second cycle compared with the first cycle. The time needed for recovery of the
leukocyte and neutrophil counts to reach 4,000/㎣after the start of each chemotherapy, respectively, was also significantly shorter in the second cycle than the first cycle.
@ES Conclusion:
@EN These results suggest that rhG-CSF is very useful drug to overcone the neutropenia induced by EAP chemotherapy, however, rhG-CSF does not affect lymphocyte, monocyte, eosionophil and basophil counts, although further studies are required to
confirm
the effect of rhG-CSF on monocytes.㎣㎣
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|